The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.5K Targets. Of those, 1.6M data for 772K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

21 articles for RK Hom


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Cmpds
Data
Article Title
Organization
28
Design and synthesis of hydroxyethylamine (HEA) BACE-1 inhibitors: prime side chromane-containing inhibitors.EBI
Elan Pharmaceuticals
30
Design and synthesis of highly selective, orally active Polo-like kinase-2 (Plk-2) inhibitors.EBI
Elan Pharmaceuticals
2
Design and synthesis of thiophene dihydroisoquinolines as novel BACE1 inhibitors.EBI
Elan Pharmaceuticals
17
Structure-based design of novel dihydroisoquinoline BACE-1 inhibitors that do not engage the catalytic aspartates.EBI
Elan Pharmaceuticals
42
Improving the permeability of the hydroxyethylamine BACE-1 inhibitors: structure-activity relationship of P2' substituents.EBI
Elan Pharmaceuticals
41
Design and synthesis of cell potent BACE-1 inhibitors: structure-activity relationship of P1' substituents.EBI
Elan Pharmaceuticals
42
Design of substrate-based inhibitors of human beta-secretase.EBI
TBA
29
Design and synthesis of brain penetrant selective JNK inhibitors with improved pharmacokinetic properties for the prevention of neurodegeneration.EBI
Elan Pharmaceuticals
33
Design and synthesis of a novel, orally active, brain penetrant, tri-substituted thiophene based JNK inhibitor.EBI
Elan Pharmaceuticals
32
Highly selective c-Jun N-terminal kinase (JNK) 2 and 3 inhibitors with in vitro CNS-like pharmacokinetic properties prevent neurodegeneration.EBI
Elan Pharmaceuticals
57
Design and synthesis of disubstituted thiophene and thiazole based inhibitors of JNK.EBI
Elan Pharmaceuticals
19
Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model.EBI
Elan Pharmaceuticals
44
Design and synthesis of hydroxyethylamine (HEA) BACE-1 inhibitors: structure-activity relationship of the aryl region.EBI
Elan Pharmaceuticals
38
Design and synthesis of statine-based cell-permeable peptidomimetic inhibitors of human beta-secretase.EBI
Elan Pharmaceuticals
29
N-Bridged bicyclic sulfonamides as inhibitors of gamma-secretase.EBI
Elan Pharmaceuticals
48
Design, synthesis, and structure-activity relationship of novel orally efficacious pyrazole/sulfonamide based dihydroquinoline gamma-secretase inhibitors.EBI
Elan Pharmaceuticals
7
Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitorsBDB
Abbvie Deutschland
4
Lactosamine-Based Derivatives as Tools to Delineate the Biological Functions of Galectins: Application to Skin Tissue Repair.BDB
Universit�� De Nantes
563
Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitorsBDB
Merck Sharp & Dohme
20
Inhibitors of the Diadenosine Tetraphosphate Phosphorylase Rv2613c of Mycobacterium tuberculosis.BDB
University of Konstanz
8
Synthesis and biological activity of N-aryl-2-aminothiazoles: potent pan inhibitors of cyclin-dependent kinases.BDB
Bristol Myers Squibb